tiprankstipranks
Regen Biopharma (RGBP)
OTHER OTC:RGBP
US Market
Holding RGBP?
Track your performance easily

Regen Biopharma (RGBP) Income Statement

117 Followers

Regen Biopharma Income Statement

Last quarter (Q ), Regen Biopharma's total revenue was $59.06K, an increase of 86.68% from the same quarter last year. In Q, Regen Biopharma's net income was $-117.11K. See Regen Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
$ 208.84K$ 236.56K$ 235.52K$ 61.19K$ 110.00K$ 110.00K
Cost of Revenue
--$ -117.25K---
Gross Profit
$ 181.41K$ 126.56K$ 242.77K$ 61.19K$ 110.00K$ 110.00K
Operating Expense
$ 588.31K$ 923.51K$ 575.12K$ 261.96K$ 209.32K$ 866.78K
Operating Income
$ -416.97K$ -686.95K$ -339.61K$ -200.77K$ -209.32K$ -756.78K
Net Non Operating Interest Income Expense
$ -48.89K$ 309.45K$ 254.83K$ -315.78K$ -333.41K$ -293.87K
Other Income Expense
$ 209.47K$ 2.15M$ 3.04M$ 5.40M$ -4.57M$ 56.08K
Pretax Income
$ -710.39K$ 1.16M$ 2.44M$ -6.77M$ 3.41M$ -2.68M
Tax Provision
--$ 300.00K---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -688.56K$ 1.02M$ 2.23M$ -6.77M$ 2.73M$ -2.68M
Basic EPS
$ -0.13$ 0.29----
Diluted EPS
$ -0.13$ 0.29----
Basic Average Shares
$ 15.13M$ 3.54M$ 3.14M$ 2.01M$ 939.90K$ 1.38M
Diluted Average Shares
$ 15.13M$ 3.54M-$ 2.01M$ 939.90K$ 1.38M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 588.31K$ 923.51K$ 575.12K$ 261.96K$ 209.32K$ 866.78K
Net Income From Continuing And Discontinued Operation
$ -701.57K$ 1.02M$ 2.23M$ -6.77M$ 2.73M$ -2.68M
Normalized Income
$ -602.34K$ 913.64K----
Interest Expense
------
EBIT
$ -662.40K$ 1.22M$ 2.65M$ -6.40M$ 4.36M$ -2.39M
EBITDA
$ -653.70K$ 1.22M$ 2.65M$ -6.40M$ 4.36M$ -982.12K
Currency in USD

Regen Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis